Cargando…

P643: CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE

Detalles Bibliográficos
Autores principales:	Ghia, Paolo, Pareek, Manan, Apkarian Bourjlian, Shogheeg, Bajwa, Naghmana, J. Corry, Anthony, Jannuru, Suman, Kreuzbauer, Georg, Abdel-Qadir, Husam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429346/ http://dx.doi.org/10.1097/01.HS9.0000969476.05517.0d

Ejemplares similares

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Memorandum 643
por: CERN. Geneva. SPS-PS Experiments Committee
Publicado: (2000)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
por: Ghia, Paolo, et al.
Publicado: (2022)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
por: Skarbnik, Alan, et al.
Publicado: (2023)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

MCTS: (Exams 70-640, 70-642 and 70-643)
por: Panek, William
Publicado: (2011)

The Real MCTS/MCITP Exam 70-643 Prep Kit
por: Posey, Brien, et al.
Publicado: (2011)

Characterization of WY 14,643 and its Complex with Aldose Reductase
por: Sawaya, Michael R., et al.
Publicado: (2016)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

X-ray emission from the cluster around E 1821+643
por: Saxton, R D, et al.
Publicado: (1997)

SAT-643 Predictors of Technology Success in Cystic Fibrosis Related Diabetes
por: Jain, Ashna, et al.
Publicado: (2020)

643. Trends, outcomes and cost analysis of Streptococcus urinary antigen testing
por: Bathina, Pradeep, et al.
Publicado: (2020)

Residue 6.43 defines receptor function in class F GPCRs
por: Turku, Ainoleena, et al.
Publicado: (2021)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Teglgaard, Rebecca, et al.
Publicado: (2023)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
por: Wallace, Danielle S., et al.
Publicado: (2023)

MicroRNA-643 regulates the expression of ZEB1 and inhibits tumorigenesis in osteosarcoma
por: Wang, Huan, et al.
Publicado: (2017)

MicroRNA-643 regulates the expression of ZEB1 and inhibits tumorigenesis in osteosarcoma
por: Wang, Huan, et al.
Publicado: (2022)

PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
por: Innocenti, Idanna, et al.
Publicado: (2023)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
por: Lin, David Y., et al.
Publicado: (2023)

A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M(27) in human plasma and application to a human pharmacokinetic study
por: Valluri, Venkat Rao, et al.
Publicado: (2022)

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
por: Isaac, Krista, et al.
Publicado: (2020)

Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration
por: Oyama, Takashi, et al.
Publicado: (2023)

MCTS 70-643 exam cram: Windows server 2008 applications infrastructure, configuring
por: Regan, Patrick E
Publicado: (2009)

Draft Genome Sequence of Rhodomicrobium udaipurense JA643(T) with Special Reference to Hopanoid Biosynthesis
por: Tushar, L., et al.
Publicado: (2014)

Draft genome sequence of Acinetobacter pittii ST643 shared by cystic fibrosis patients
por: Rocha, Géssica A, et al.
Publicado: (2016)

FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report
por: Mathew, Anoopa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g08u5uqsd35ep3n0nl5t8ugk0c